Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas
- Authors
- Ryu, Je Il; Han, Myun Hoon; Cheong, Jin Hwan; Kim, Jae Min; Kim, Choong Hyun
- Issue Date
- Mar-2017
- Publisher
- FUTURE MEDICINE LTD
- Keywords
- adoptive immunotherapy; clinical trials; cytokine-induced killer (CIK) cells; cytotoxicity; glioma; immune response
- Citation
- IMMUNOTHERAPY, v.9, no.5, pp.411 - 421
- Indexed
- SCIE
SCOPUS
- Journal Title
- IMMUNOTHERAPY
- Volume
- 9
- Number
- 5
- Start Page
- 411
- End Page
- 421
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/152850
- DOI
- 10.2217/imt-2017-0003
- ISSN
- 1750-743X
- Abstract
- The therapeutic outcome for those with malignant glioma is poor, even though diverse therapeutic modalities have been developed. Immunotherapy has emerged as a therapeutic approach for malignant gliomas, making it possible to selectively treat tumors while sparing normal tissue. Here, we review clinical trials of adoptive immunotherapy approaches for malignant gliomas. We also describe a clinical trial that examined the efficacy and safety of autologous cytokine-induced killer (CIK) cells along with concomitant chemoradiotherapy for newly diagnosed glioblastoma. These CIK cells identify and kill autologous tumor cells. This review focuses on the use of adoptive immunotherapy for malignant gliomas and reviews the current literature on the concept of antitumor activity mediated by CIK cells.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 신경외과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/152850)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.